Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Brain Chemistry in Depression
NCT01558063Phase 2Completed
- Sponsor
- Columbia University
- Start
- Feb 2012
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ketamine in major depressive disorder (MDD) (7 arms), sponsored by Columbia University. Primary endpoint: Number of Responders 24-hours Post-ketamine Infusion. Started Feb 2012; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01558063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01558063.